AbbVie annual ebitda
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie EBITDA Growth & History (ABBV)
AbbVie's calculated EBITDA was $23.21B for fiscal 2025.
View full AbbVie company overviewAbbVie annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $23.21B | $5.69B | +32.48% |
| 2024 | 2024-12-31 | $17.52B | −$3.93B | −18.33% |
| 2023 | 2023-12-31 | $21.45B | −$5.13B | −19.29% |
| 2022 | 2022-12-31 | $26.58B | $139.0M | +0.53% |
| 2021 | 2021-12-31 | $26.45B | $8.61B | +48.28% |
| 2020 | 2020-12-31 | $17.83B | $2.83B | +18.89% |
| 2019 | 2019-12-31 | $15.00B | $6.85B | +84.09% |
| 2018 | 2018-12-31 | $8.15B | −$2.90B | −26.24% |
| 2017 | 2017-12-31 | $11.05B | $517.0M | +4.91% |
| 2016 | 2016-12-31 | $10.53B | $2.16B | +25.75% |
| 2015 | 2015-12-31 | $8.37B | $4.18B | +99.50% |
| 2014 | 2014-12-31 | $4.20B | −$2.36B | −36.03% |
| 2013 | 2013-12-31 | $6.56B | −$406.0M | −5.83% |
| 2012 | 2012-12-31 | $6.97B | $2.08B | +42.42% |
| 2011 | 2011-12-31 | $4.89B | — | — |
AbbVie quarterly ebitda
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.33B | $1.35B | +19.28% |
| Q1 2026 | 2026-03-31 | $5.93B | $154.0M | +2.67% |
| Q4 2025 | 2025-12-31 | $6.47B | $5.82B | +899.38% |
| Q3 2025 | 2025-09-30 | $4.00B | −$1.93B | −32.52% |
| Q2 2025 | 2025-06-30 | $6.98B | $898.0M | +14.76% |
| Q1 2025 | 2025-03-31 | $5.77B | $900.0M | +18.47% |
| Q4 2024 | 2024-12-31 | $647.0M | −$4.63B | −87.75% |
| Q3 2024 | 2024-09-30 | $5.92B | $1.45B | +32.28% |
| Q2 2024 | 2024-06-30 | $6.08B | −$721.0M | −10.60% |
| Q1 2024 | 2024-03-31 | $4.87B | −$23.0M | −0.47% |
| Q4 2023 | 2023-12-31 | $5.28B | −$2.45B | −31.71% |
| Q3 2023 | 2023-09-30 | $4.48B | −$2.31B | −34.01% |
| Q2 2023 | 2023-06-30 | $6.80B | $1.50B | +28.41% |
| Q1 2023 | 2023-03-31 | $4.89B | −$1.88B | −27.70% |
| Q4 2022 | 2022-12-31 | $7.73B | $676.0M | +9.58% |
| Q3 2022 | 2022-09-30 | $6.78B | $355.0M | +5.52% |
| Q2 2022 | 2022-06-30 | $5.30B | −$1.34B | −20.23% |
| Q1 2022 | 2022-03-31 | $6.77B | $452.0M | +7.15% |
| Q4 2021 | 2021-12-31 | $7.06B | $1.22B | +20.80% |
| Q3 2021 | 2021-09-30 | $6.43B | $899.0M | +16.26% |
| Q2 2021 | 2021-06-30 | $6.64B | $4.34B | +188.66% |
| Q1 2021 | 2021-03-31 | $6.32B | $2.16B | +51.80% |
| Q4 2020 | 2020-12-31 | $5.84B | $1.38B | +30.82% |
| Q3 2020 | 2020-09-30 | $5.53B | $2.41B | +77.24% |
| Q2 2020 | 2020-06-30 | $2.30B | −$1.60B | −41.03% |
| Q1 2020 | 2020-03-31 | $4.16B | $649.0M | +18.47% |
| Q4 2019 | 2019-12-31 | $4.46B | $6.46B | — |
| Q3 2019 | 2019-09-30 | $3.12B | −$474.0M | −13.19% |
| Q2 2019 | 2019-06-30 | $3.90B | $697.0M | +21.75% |
| Q1 2019 | 2019-03-31 | $3.51B | $165.0M | +4.93% |
| Q4 2018 | 2018-12-31 | −$2.00B | −$4.15B | — |
| Q3 2018 | 2018-09-30 | $3.59B | $521.0M | +16.95% |
| Q2 2018 | 2018-06-30 | $3.21B | $164.0M | +5.39% |
| Q1 2018 | 2018-03-31 | $3.35B | $567.0M | +20.39% |
| Q4 2017 | 2017-12-31 | $2.15B | −$491.0M | −18.58% |
| Q3 2017 | 2017-09-30 | $3.07B | $408.0M | +15.31% |
| Q2 2017 | 2017-06-30 | $3.04B | $365.0M | +13.64% |
| Q1 2017 | 2017-03-31 | $2.78B | $235.0M | +9.23% |
| Q4 2016 | 2016-12-31 | $2.64B | $268.0M | +11.29% |
| Q3 2016 | 2016-09-30 | $2.67B | $553.0M | +26.18% |
| Q2 2016 | 2016-06-30 | $2.68B | $634.0M | +31.05% |
| Q1 2016 | 2016-03-31 | $2.55B | $701.0M | +37.99% |
| Q4 2015 | 2015-12-31 | $2.37B | $2.60B | — |
| Q3 2015 | 2015-09-30 | $2.11B | $960.0M | +83.33% |
| Q2 2015 | 2015-06-30 | $2.04B | $325.0M | +18.93% |
| Q1 2015 | 2015-03-31 | $1.84B | $295.0M | +19.03% |
| Q4 2014 | 2014-12-31 | −$222.0M | −$1.96B | — |
| Q3 2014 | 2014-09-30 | $1.15B | −$453.0M | −28.22% |
| Q2 2014 | 2014-06-30 | $1.72B | $28.0M | +1.66% |
| Q1 2014 | 2014-03-31 | $1.55B | $18.0M | +1.17% |
| Q4 2013 | 2013-12-31 | $1.74B | −$395.0M | −18.54% |
| Q3 2013 | 2013-09-30 | $1.60B | −$218.0M | −11.96% |
| Q2 2013 | 2013-06-30 | $1.69B | −$28.0M | −1.63% |
| Q1 2013 | 2013-03-31 | $1.53B | $235.0M | +18.12% |
| Q4 2012 | 2012-12-31 | $2.13B | — | — |
| Q3 2012 | 2012-09-30 | $1.82B | — | — |
| Q2 2012 | 2012-06-30 | $1.72B | — | — |
| Q1 2012 | 2012-03-31 | $1.30B | — | — |
AbbVie ebitda trends
Over the last five fiscal years, AbbVie's ebitda increased from $17.83B to $23.21B, a change of $5.38B. The latest reported quarter, Q2 2026, shows $8.33B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
